Technology: Scientific Publications


Kappel Buhl, A. et al.
Doxorubicin response prediction in neoadjuvant breast cancer therapy
Journal of Clinical Oncology 2019 37:15                  

Kappel Buhl, A. et al.
A drug response predictor to guide treatment for breast cancer
Pharmacogenomics, 2019 (Ahead of Print)


Chen, J. et al.
A 71-gene signature of TRAIL sensitivity in cancer Cells
Mol Cancer Ther. 2011. 10.1158/1535-7163

Miller, I. et al.
Market access challenges in the EU for high value diagnostic tests
Personalized Medicine. 2011. 8(2): 137-148

Oncology Venture is now

Allarity Therapeutics

At Allarity Therapeutics, we are defining a bright future for patients in a new paradigm of precision cancer treatments. Our mission is to bring clarity to personalized oncology medicines, marrying innovative therapies and superior companion diagnostics, to help fully realize the promise of personalized cancer care.

Allarity Therapeutics Logo